Dianthus Therapeutics, Inc. /De/ (DNTH) Stock Price & Analysis
Dianthus Therapeutics, Inc. /De/ (DNTH) fell 0.88% to USD 103.87 as of July 26, 2026 at 06:45 UTC, according to Nexqual real-time market data.
DNTH last closed at USD 104.79; the session ranged USD 102.72–106.28 on volume of 670,799 shares. Market capitalization is $5.68B, with a 52-week range of USD 18.08–107.99 (NCM). Source: Nexqual, July 26, 2026 at 06:45 UTC.
Key Statistics (as of July 26, 2026 at 06:45 UTC)
| Price | USD 103.87 |
|---|---|
| Change | ▼ 0.88% (down) |
| Previous Close | USD 104.79 |
| Open | USD 106.12 |
| Day Range | USD 102.72 – 106.28 |
| 52-Week Range | USD 18.08 – 107.99 |
| Volume | 670,799 shares |
| Market Cap | $5.68B |
| Exchange | NCM |
Technical Analysis (DNTH)
Nexqual's technical model rates DNTH "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 26, 2026 at 06:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.07 (neutral) |
| vs SMA50 | Above (USD 90.6) |
| MACD | 4.13 (positive) |
Analyst Ratings (DNTH)
Wall Street analysts rate DNTH "Strong Buy" based on 12 analysts, with a mean price target of USD 128.58 (range USD 105–200), per Nexqual as of July 26, 2026 at 06:45 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 128.58 |
| High Target | USD 200 |
| Low Target | USD 105 |
| Buy / Hold / Sell | 15 / 0 / 0 |
Earnings (DNTH)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.91 |
| Revenue Estimate | $248,750 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.85 vs est -1.1 ▲ beat |
| 2025-12-31 | USD -1.43 vs est -1.03 ▼ miss |
| 2025-09-30 | USD -0.97 vs est -0.9 ▼ miss |
| 2025-06-30 | USD -0.88 vs est -0.87 ▼ miss |
Source: Nexqual, July 26, 2026 at 06:45 UTC.
Financials & Fundamentals (DNTH)
| Total Revenue | $1.34M |
|---|---|
| Revenue Growth (YoY) | -60.20% |
| Gross Margin | +100.00% |
| Operating Margin | -10050.32% |
| Profit Margin | +0.00% |
| ROE | -22.70% |
| Debt / Equity | 0.11 |
| Current Ratio | 29.25 |
| Total Cash | $1.11B |
| Total Debt | $1.36M |
| Free Cash Flow | $-71.03M |
Source: Nexqual, July 26, 2026 at 06:45 UTC.
Financial Health Score (DNTH)
Nexqual rates Dianthus Therapeutics, Inc. /De/'s overall financial health "Weak" across five dimensions, as of July 26, 2026 at 06:45 UTC.
| Growth | Critical — Revenue -67% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1.11B cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$71M, burning cash |
| Efficiency | Critical — ROE -23%, ROA -15.0% |
Ownership (DNTH)
| Insider Ownership | +0.13% |
|---|---|
| Institutional Ownership | +121.52% |
| Shares Outstanding | 54.67M |
| Float | 54.60M |
| Short % of Float | +19.42% |
Source: Nexqual, July 26, 2026 at 06:45 UTC.
Leadership (DNTH)
Dianthus Therapeutics, Inc. /De/ is led by Marino Garcia (age 59), President, CEO & Director, per Nexqual as of July 26, 2026 at 06:45 UTC.
| President, CEO & Director | Marino Garcia (age 59) |
|---|---|
| Executive VP, CFO, Chief Business Officer & Treasurer | Ryan Savitz (age 36) |
Major Backers & Investors (DNTH)
Notable institutional backers of Dianthus Therapeutics, Inc. /De/ include FMR, LLC, Fidelity, RA Capital Management, L.P., according to Nexqual as of July 26, 2026 at 06:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.21% |
| Fidelity | 5.93% |
| RA Capital Management, L.P. | 4.78% |
| Wellington Management | 4.75% |
| Fairmount Funds Management LLC | 4.64% |
| Avidity Partners Management, LP | 3.85% |
| Octagon Capital Advisors LP | 3.56% |
| TCG Crossover Management, LLC | 3.07% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.86% |
| BlackRock | 7.38% |
Source: Nexqual, July 26, 2026 at 06:45 UTC.
From Dianthus Therapeutics, Inc. /De/'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs.
Partnerships
- Our First and Potentially Best-In-Class Bifunctional BDCA2 and BAFF/APRIL Inhibitor (DNTH212) On October 16, 2025, we entered into an exclusive license agreement with Nanjing Leads Biolabs Co., Ltd. ("Leads") for DNTH212, a first and potentially best-in-class bifunctional BDCA2 and BAFF/APRIL inhibitor.
- We are currently a party to a license agreement with Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia") for claseprubart, pursuant to which Tenacia has development and commercialization rights in the People's Republic of China, including Hong Kong, Macau, and Taiwan ("Greater China").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | USD 102.13 | ▲ 2.98% |
| ORKA | Oruka Therapeutics, Inc. | USD 92.16 | ▼ 0.4% |
| ELVN | Enliven Therapeutics, Inc. | USD 52.95 | ▲ 0.19% |
| APGE | Apogee Therapeutics, Inc. | USD 134.28 | ▲ 0.15% |
| MLYS | Mineralys Therapeutics, Inc. | USD 26.71 | ▼ 1.11% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 06:45 UTC. This page is informational and not investment advice.